Cellectis
CLLS
34 hedge funds and large institutions have $30.5M invested in Cellectis in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 6 closing their positions.
575% more call options, than puts
Call options by funds: $27K | Put options by funds: $4K
68% more capital invested
Capital invested by funds: $18.1M → $30.5M (+$12.3M)
50% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 6
10% more funds holding
Funds holding: 31 → 34 (+3)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
6.87% less ownership
Funds ownership: 20.66% → 13.79% (-6.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$201K |
| 2 |
Two Sigma Investments
New York
|
+$124K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$46.3K |
| 4 |
OC
Oppenheimer & Co
New York
|
+$27.8K |
| 5 |
LPL Financial
San Diego,
California
|
+$20.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.73M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$824K |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
-$610K |
| 4 |
D.E. Shaw & Co
New York
|
-$74.5K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$39.2K |
CLLS Hedge Fund Activity: Q4 2023 in Review
34 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q4 2023, worth a combined $30.5M — up 68% from $18.1M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CLLS positions and 6 closed out — a net gain of 3 holders — while 7 added to existing stakes and 7 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $201K. The largest seller was Millennium Management, exiting entirely with an estimated $1.73M sold.
- 34 institutional investors held Cellectis (CLLS) as of Q4 2023, up from 31 in Q3 2023.
- Funds reported $30.5M of Cellectis stock for Q4 2023, up 68% quarter-over-quarter.
- 9 funds opened new Cellectis positions in Q4 2023 and 6 closed out, a net change of +3 holders.
- The largest Cellectis buyer in Q4 2023 was Morgan Stanley, an estimated $201K added.
- The largest Cellectis seller in Q4 2023 was Millennium Management, an estimated $1.73M sold.
Based on aggregated 13F filings for Q4 2023.